407 related articles for article (PubMed ID: 15720262)
21. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
22. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
Liaw TY; Chang MH; Kavallaris M
Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
[TBL] [Abstract][Full Text] [Related]
23. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
[TBL] [Abstract][Full Text] [Related]
24. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?
Ferlini C; Raspaglio G; Cicchillitti L; Mozzetti S; Prislei S; Bartollino S; Scambia G
Curr Cancer Drug Targets; 2007 Dec; 7(8):704-12. PubMed ID: 18220531
[TBL] [Abstract][Full Text] [Related]
25. [Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules].
Tabaczar S; Koceva-Chyła A; Matczak K; Gwoździński K
Postepy Hig Med Dosw (Online); 2010 Nov; 64():568-81. PubMed ID: 21109709
[TBL] [Abstract][Full Text] [Related]
26. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
27. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
28. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
29. Tubulin inhibitors: a patent survey.
Nepali K; Ojha R; Sharma S; Bedi PM; Dhar KL
Recent Pat Anticancer Drug Discov; 2014 May; 9(2):176-220. PubMed ID: 23746164
[TBL] [Abstract][Full Text] [Related]
30. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
Fürst R; Vollmar AM
Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
[TBL] [Abstract][Full Text] [Related]
31. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
Wilson L; Jordan MA
J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
[TBL] [Abstract][Full Text] [Related]
32. Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation.
Senese S; Lo YC; Gholkar AA; Li CM; Huang Y; Mottahedeh J; Kornblum HI; Damoiseaux R; Torres JZ
Oncotarget; 2017 Nov; 8(61):104007-104021. PubMed ID: 29262617
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials.
Kumar B; Kumar R; Skvortsova I; Kumar V
Curr Cancer Drug Targets; 2017; 17(4):357-375. PubMed ID: 27697026
[TBL] [Abstract][Full Text] [Related]
34. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D; Bronte G; Passiglia F; Calò V; Castiglia M; Di Piazza F; Barraco N; Cangemi A; Catarella MT; Insalaco L; Listì A; Maragliano R; Massihnia D; Perez A; Toia F; Cicero G; Bazan V
Anal Cell Pathol (Amst); 2015; 2015():690916. PubMed ID: 26484003
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance.
Manzoor S; Bilal A; Khan S; Ullah R; Iftikhar S; Emwas AH; Alazmi M; Gao X; Jawaid A; Saleem RSZ; Faisal A
Sci Rep; 2018 Feb; 8(1):3305. PubMed ID: 29459693
[TBL] [Abstract][Full Text] [Related]
36. Microtubules in apoptosis induction: are they necessary?
Estève MA; Carré M; Braguer D
Curr Cancer Drug Targets; 2007 Dec; 7(8):713-29. PubMed ID: 18220532
[TBL] [Abstract][Full Text] [Related]
37. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.
Abal M; Andreu JM; Barasoain I
Curr Cancer Drug Targets; 2003 Jun; 3(3):193-203. PubMed ID: 12769688
[TBL] [Abstract][Full Text] [Related]
38. [Microtubules and antineoplastic drugs].
Arioka H; Saijo N
Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
[TBL] [Abstract][Full Text] [Related]
39. Microtubule dynamics as a target in oncology.
Risinger AL; Giles FJ; Mooberry SL
Cancer Treat Rev; 2009 May; 35(3):255-61. PubMed ID: 19117686
[TBL] [Abstract][Full Text] [Related]
40. Marine Derived Anticancer Drugs Targeting Microtubule.
De O; Chatterji BP
Recent Pat Anticancer Drug Discov; 2017; 12(2):102-127. PubMed ID: 28067173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
